Results for “phase arc”

Use when the user asks to "build the norm card for this platform", "what are the char limits and visible-fold cutoffs here", "is the LinkedIn link-in-first-comment thing documented or folklore", or "which of our platform cards are stale"; maintains the dated, versioned per-platform norm cards in the references/platforms/ pack — char limits, visible-fold cutoffs, hashtag norms, format/aspect specs, link and first-comment placement, disclosure-label mechanics, algorithm emphases (e.g. 小红书 search+saves weighting) — every row labeled platform-documented (official doc, Measured) or Estimated-folklore (named source) with last-verified and review-by dates, and any card past its review date flagged stale rather than trusted. Extends the single pack in place; never forks a second one. Not for picking which channels to run — use channel-portfolio-planner. 平台规范卡/字符限制/折叠线/话题标签/算法侧重/过期标记

The English summary is being prepared. Showing the original description.

Use when the user asks to "map what our surfaces say today", "inventory our current messaging", or "find the gap between what we say and what we mean"; produces the narrative baseline — a surface-by-surface inventory of what every owned touchpoint (homepage, pricing, docs, decks, social bios, email footers) claims RIGHT NOW, each line labeled Measured / User-provided / Estimated, plus a per-surface gap read vs the intended message and the drift-baseline snapshot the Evaluate phase measures future drift against. Not for authoring the canon — use message-system-architect; not for scoring the surfaces or running the vetoes — use narrative-quality-auditor. 现状叙事盘点/各触点口径/意图差距/漂移基线

The English summary is being prepared. Showing the original description.

Use when the user asks to "test our messaging before we scale it", "design a message-market-fit panel", or "run a 5-second comprehension test on our new tagline"; produces a message-test design spec — hypothesis, panel and recruit criteria, comprehension / 5-second / message-market-fit (Wynter-style) protocols, stimulus set drawn from the canon, success thresholds, and a stop/revise decision rule — for the TALE Evaluate phase so the message is validated before any paid scale. It designs the test; it never runs the experiment or adjudicates a claim. Not for running the panel or A/B experiment — use send-experiment-designer or ad-test-designer; not for analyzing the results — use performance-analyzer; not for authoring the message itself — use message-system-architect. 消息测试/理解度测试/面板设计/五秒测试/消息市场契合

The English summary is being prepared. Showing the original description.

Use when the user asks to "analyze my target audience", "build an audience profile for influencer targeting", "research a niche community", or "deep-dive a subculture before partnering with creators"; in audience mode produces demographic/psychographic profiles, a platform-priority matrix, named personas, and an influencer-selection criteria set, and in niche mode produces a community map, culture decode (language/norms/taboos), key-voice tiers, a Brand Fit Score, and a phased entry strategy. Not for finding specific creators to contract — use influencer-discovery; not for scoring a shortlist on Suitability — use fit-scorer. 目标受众画像/人群分析 · 细分社群/亚文化调研

The English summary is being prepared. Showing the original description.

Guide for optimizing MSBuild incremental builds. Only activate in MSBuild/.NET build context. USE FOR: builds slower than expected on subsequent runs, 'nothing changed but it rebuilds anyway', diagnosing why targets re-execute unnecessarily, fixing broken no-op builds. Covers 8 common causes: missing Inputs/Outputs on custom targets, volatile properties in output paths (timestamps/GUIDs), file writes outside tracked Outputs, missing FileWrites registration, glob changes, Visual Studio Fast Up-to-Date Check (FUTDC) issues. Key diagnostic: look for 'Building target completely' vs 'Skipping target' in binlog. DO NOT USE FOR: first-time build slowness (use build-perf-baseline), parallelism issues (use build-parallelism), evaluation-phase slowness (use eval-performance), non-MSBuild build systems. INVOKES: binlog MCP server tools (overview, search, target details); falls back to dotnet build /bl, binlog replay with diagnostic verbosity.

The English summary is being prepared. Showing the original description.

Applies standard AI review policy guidelines for upstream (design) phase reviews.

The English summary is being prepared. Showing the original description.

Multi-phase dialectical stress-test for HIGH-STAKES decisions only (architecture choices, irreversible product calls, strategic bets). Heavy-cost skill — do NOT use for routine questions, brainstorming, or simple tradeoffs. User must explicitly invoke or describe a decision they call "high-stakes", "irreversible", or "needs stress-testing". Triggers: "stress test this decision", "dialectic on", "challenge this thesis", "should I really".

The English summary is being prepared. Showing the original description.

You MUST use this when building projects end-to-end. Orchestrates all 12 team roles — automatically switches between CTO, architect, PM, engineers, SRE, security, DBA, QA, and EM based on the current phase of work. Starts with brainstorming before any implementation.

The English summary is being prepared. Showing the original description.

Designs Bayesian clinical trials including Phase I dose-finding (BOIN, CRM, EWOC, mTPI-2), meta-analytic-predictive (MAP) priors with robust mixtures for external data borrowing, EXNEX for basket trials, hierarchical models for safety AE (Berry-Berry), Bayesian platform trials (I-SPY 2, GBM AGILE, REMAP-CAP), and posterior probability stopping rules. Covers FDA Bayesian Devices Guidance (2010), FDA Bayesian Methodology in Drugs Draft (January 2026), BOIN Fit-for-Purpose qualification (December 2021), and Project Optimus dose-optimisation. Use when designing dose-finding studies, platform trials, or sensitivity analyses with informative priors.

The English summary is being prepared. Showing the original description.

Parses, queries, converts, and extracts from GTF and GFF3 gene-model annotation files - walking the gene/transcript/exon/CDS hierarchy with gffutils (queryable SQLite DB), converting formats and extracting transcript/CDS/protein FASTA with gffread, slurping to dataframes with gtfparse/pyranges, and sanitizing malformed files with AGAT. Covers the 1-based-inclusive vs 0-based BED coordinate conversion (start-1 only), deriving implicit features (introns/UTRs/TSS), phase-not-frame, the stop-codon-in-or-out-of-CDS convention, and the chr1-vs-1 seqid and gene-ID-version mismatches that silently produce all-zero count matrices and dropped joins. Use when extracting features or sequences from an annotation, converting GTF<->GFF3 or GTF->BED, traversing the gene tree, or diagnosing a coordinate/provenance mismatch upstream of counting or DE.

The English summary is being prepared. Showing the original description.

Calls HLA class I and class II alleles at 2/4/6/8-field resolution from WGS/WES/RNA-seq/long-read data using OptiType, HLA-LA, T1K, Polysolver, HLA-HD, arcasHLA, StarPhase, or HIBAG imputation. Use when typing for HSCT, solid-organ transplant, neoantigen prediction, PGx screening (B*57:01, B*15:02, etc.), or disease-association studies, with reconciliation across tools and IPD-IMGT/HLA version mismatch handling.

The English summary is being prepared. Showing the original description.

Designs Bayesian clinical trials including Phase I dose-finding (BOIN, CRM, EWOC, mTPI-2), meta-analytic-predictive (MAP) priors with robust mixtures for external data borrowing, EXNEX for basket trials, hierarchical models for safety AE (Berry-Berry), Bayesian platform trials (I-SPY 2, GBM AGILE, REMAP-CAP), and posterior probability stopping rules. Covers FDA Bayesian Devices Guidance (2010), FDA Bayesian Methodology in Drugs Draft (January 2026), BOIN Fit-for-Purpose qualification (December 2021), and Project Optimus dose-optimisation. Use when designing dose-finding studies, platform trials, or sensitivity analyses with informative priors.

The English summary is being prepared. Showing the original description.

Create a detailed, step-by-step implementation plan for a feature or project. Load when the user asks to plan a feature, create a technical roadmap, break down a PRD into tasks, design an implementation strategy, or sequence engineering work. Also triggers on "how should we build this", "implementation plan for", "technical breakdown", "task list for", or any request to turn a high-level requirement into a concrete execution plan. Supports phased rollouts, architecture-first, and MVP-focused planning.

The English summary is being prepared. Showing the original description.

Parses, queries, converts, and extracts from GTF and GFF3 gene-model annotation files - walking the gene/transcript/exon/CDS hierarchy with gffutils (queryable SQLite DB), converting formats and extracting transcript/CDS/protein FASTA with gffread, slurping to dataframes with gtfparse/pyranges, and sanitizing malformed files with AGAT. Covers the 1-based-inclusive vs 0-based BED coordinate conversion (start-1 only), deriving implicit features (introns/UTRs/TSS), phase-not-frame, the stop-codon-in-or-out-of-CDS convention, and the chr1-vs-1 seqid and gene-ID-version mismatches that silently produce all-zero count matrices and dropped joins. Use when extracting features or sequences from an annotation, converting GTF<->GFF3 or GTF->BED, traversing the gene tree, or diagnosing a coordinate/provenance mismatch upstream of counting or DE.

The English summary is being prepared. Showing the original description.

Calls HLA class I and class II alleles at 2/4/6/8-field resolution from WGS/WES/RNA-seq/long-read data using OptiType, HLA-LA, T1K, Polysolver, HLA-HD, arcasHLA, StarPhase, or HIBAG imputation. Use when typing for HSCT, solid-organ transplant, neoantigen prediction, PGx screening (B*57:01, B*15:02, etc.), or disease-association studies, with reconciliation across tools and IPD-IMGT/HLA version mismatch handling.

The English summary is being prepared. Showing the original description.

Designs Bayesian clinical trials including Phase I dose-finding (BOIN, CRM, EWOC, mTPI-2), meta-analytic-predictive (MAP) priors with robust mixtures for external data borrowing, EXNEX for basket trials, hierarchical models for safety AE (Berry-Berry), Bayesian platform trials (I-SPY 2, GBM AGILE, REMAP-CAP), and posterior probability stopping rules. Covers FDA Bayesian Devices Guidance (2010), FDA Bayesian Methodology in Drugs Draft (January 2026), BOIN Fit-for-Purpose qualification (December 2021), and Project Optimus dose-optimisation. Use when designing dose-finding studies, platform trials, or sensitivity analyses with informative priors.

The English summary is being prepared. Showing the original description.

Generates comprehensive, workable unit tests for any programming language using a multi-agent pipeline. Use when asked to generate tests, write unit tests, improve test coverage, add test coverage, create test files, or test a codebase. Supports C#, TypeScript, JavaScript, Python, Go, Rust, Java, and more. Orchestrates research, planning, and implementation phases to produce tests that compile, pass, and follow project conventions.

The English summary is being prepared. Showing the original description.

Archive accumulated phase directories from completed milestones

The English summary is being prepared. Showing the original description.

Two-phase Apollo.io prospecting: free People Search to discover ICP-matching leads, then selective enrichment to reveal emails/phones (credits per contact). Deduplicates against CRM (Google Sheets). Supports Apollo API and MCP tools.

The English summary is being prepared. Showing the original description.